通过脱芳构化环加成合成手性稠合多环莨菪烷的方法

文档序号:1563772 发布日期:2020-01-24 浏览:35次 >En<

阅读说明:本技术 通过脱芳构化环加成合成手性稠合多环莨菪烷的方法 (Method for synthesizing chiral fused polycyclic tropanes by dearomatization cycloaddition ) 是由 王东超 成鹏鹏 郭海明 王震 谢明胜 渠桂荣 于 2019-12-10 设计创作,主要内容包括:本发明公开了通过脱芳构化环加成合成手性稠合多环莨菪烷的方法,属于有机合成技术领域。以环状亚胺叶立德1和硝基苯并呋喃2为原料,在铜盐和轴手性双膦催化下,通过不对称1,3-偶极[3+2]环加成反应得到手性稠合多环莨菪烷类化合物3。该方法具有高非对映选择性、高对映选择性的优点,产物同时具有连续的四个手性中心,为手性稠合多环莨菪烷提供了一种简便的合成途径。(The invention discloses a method for synthesizing chiral condensed polycyclic tropane by dearomatization cycloaddition, belonging to the technical field of organic synthesis. The chiral condensed polycyclic tropane compound 3 is obtained by taking cyclic imine ylide 1 and nitrobenzofuran 2 as raw materials and performing asymmetric 1, 3-dipolar [3&#43;2] cycloaddition reaction under the catalysis of copper salt and axial chiral diphosphine. The method has the advantages of high diastereoselectivity and high enantioselectivity, and the product simultaneously has four continuous chiral centers, so that a simple and convenient synthetic approach is provided for chiral condensed polycyclic tropane.)

通过脱芳构化环加成合成手性稠合多环莨菪烷的方法

技术领域

本发明具体涉及通过脱芳构化环加成合成手性稠合多环莨菪烷的方法,属于有机化学中不对称合成技术领域。

背景技术

以莨菪烷为基本骨架的多环结构广泛存在于天然产物和具有重要生理功能的药物分子中。这类化合物在临床治疗免疫、神经、精神疾病等方面发挥着关键作用。

目前手性莨菪烷化合物多以手性试剂为原料进行合成,结构比较简单,以催化不对称的方法合成结构复杂的稠环多环莨菪烷化合物的文献报道较少。现有公开报道仅有Waldmann等利用环亚胺叶立德与硝基苯乙烯[3+2]环加成反应,邓卫平等利用2-烯基吲哚和环亚胺叶立德的[3+3]环加成,分别合成了吲哚并莨菪烷类化合物;谭斌等利用异喹啉的去芳构化反应合成了苯并莨菪烷类化合物。

鉴于采用苯并呋喃类化合物的脱芳构化环加成反应,构建一类新型的手性稠化多环莨菪烷类化合物研究尚不充分,因而仍然需要继续对该领域进行探索,并开发出简单有效的合成方法。

发明内容

为了解决上述技术问题,本发明首先提供了一种结构新型的手性稠合多环莨菪烷类化合物,结构如下:

Figure BDA0002310649070000011

其中,R1选自卤素、烷基或烷氧基;R2和R3均选自烷基;R4选自卤素、硝基、烷基或烷氧基。

采用硝基取代苯并呋喃2和环状亚胺叶立德1为原料,在铜盐、有机膦配体和碱存在下,通过不对称的1,3-偶极环加成脱芳构化反应,得到手性稠合多环莨菪烷类化合物3。该方法为手性稠合多环莨菪烷类化合物的合成提供了一种温和、简便、高效的途径。

通过脱芳构化环加成合成手性稠合多环莨菪烷的方法,包括如下操作:以硝基取代苯并呋喃2和环状亚胺叶立德1为原料,在铜盐、有机膦配体和碱存在下,反应得到手性稠合多环莨菪烷3;反应方程式如下:

Figure BDA0002310649070000021

其中,R1选自卤素、C1-C4烷基或C1-C4烷氧基;R2和R3均选自C1-C7烷基;R4选自卤素、硝基、C1-C4烷基或C1-C4烷氧基。

优选地,在上述技术方案中,R1选自5-Me、5-OCH3、5-Br、4-OCH3、6-Cl等;R2选自Me、Et、Bn等;R3选自Et、n-pentyl等;R4选自5-Me、5-OCH3、5-F、5-Cl、5-Br、5-NO2、6-Me、6-OCH3、6-Br、7-OCH3、7-Br等。

进一步地,在上述技术方案中,所述有机膦配体选自L1-L9,结构如下:

在上述L1-L9磷催化剂中,优选催化剂为L6-L9。

进一步地,在上述技术方案中,铜盐选自Cu(OAc)2、Cu(OTf)2、Cu(MeCN)4ClO4、Cu(MeCN)4PF6等,碱选自碳酸钾、碳酸钠、碳酸铯、三乙胺等。

进一步地,在上述技术方案中,硝基取代苯并呋喃化合物2、环状亚胺叶立德1与铜盐、有机膦配体和碱摩尔比为1:2-2.2:0.005-0.05:0.005-0.05:0.05-0.15。

进一步地,在上述技术方案中,所述反应在有机溶剂中进行,有机溶剂选自甲基叔丁基醚、氯仿、二氯甲烷、二氯乙烷、乙腈、***或甲苯中的一种或多种。优选溶剂为甲基叔丁基醚。

进一步地,在上述技术方案中,反应温度选自25℃至-40℃。优选温度为0℃。

进一步地,在上述技术方案中,反应在惰性气体保护下进行,惰性气体优选氮气。

进一步地,得到手性稠合多环莨菪烷类化合物3可以衍生得到不同类型的衍生产物,硝基脱除生成脱硝基产物4,硝基还原生成还原为氨基的产物5,酯基还原得到还原为羟基的产物6。

Figure BDA0002310649070000031

进一步地,产物4的转化采用三丁基氢化锡和AIBN,产物5的转化采用锌粉和浓盐酸。产物6的转化采用四氢铝锂。

进一步地,在上述技术方案中,采用三丁基氢化锡和AIBN进行脱硝基生成化合物4选自80℃,硝基还原生成化合物5选自0℃。酯基还原生成化合物6选自-78℃。

发明有益效果:

本发明以硝基取代苯并呋喃2和环状亚胺叶立德1为原料,通过不对称脱芳构化[3+2]环加成反应后,一步即可得到手性稠合多环莨菪烷类化合物3,同时具有4个连续的手性中心,结构新颖,未见公开资料报道。

反应原料易得,产物非对映选择性和对映选择性高,产物dr值最高可达>20:1,反应收率和对映选择性最高分别可达91%和98%ee。产物经过脱硝基、硝基还原和酯基还原后衍生,得到不同类型多环莨菪烷4-6。

附图说明

图1为实施例11中化合物3ak单晶X衍射谱图。

具体实施方式

实施例1

以2-硝基苯并呋喃2a和环状亚胺叶立德1a生成3aa为例,进行反应条件优化,反应方程式如下:

Figure BDA0002310649070000041

Figure BDA0002310649070000051

a除非特别说明,反应的步骤如下:1a(0.22mmol),2a(0.1mmol),金属铜(5mol%),配体(5mol%),碱(10mol%),1.0mL溶剂,在N2保护下0℃反应10小时。b分离收率,cdr值通过核磁测试粗产物确定。d通过手性HPLC分析确定。e1a(0.44mmol),2a(0.2mmol),金属铜(1mol%),配体(1mol%),碱(10mol%),2.0mL溶剂。

在反应条件的筛选过程中,首先考察了催化剂对反应的影响(entries 1-9)。同时考察了不同溶剂、反应温度(-40℃至+25℃,对映选择性和收率影响不超过2%)、原料当量比、催化剂用量(0.01-0.05当量,对映选择性基本不变,收率85-87%)和不同的碱(如碳酸钾、碳酸铯、碳酸钠、三乙胺等,对映选择性和收率影响不超过2%)对反应的影响,最终确定了L9为最佳催化剂,MTBE为最佳反应溶剂,0℃为最佳反应温度。

反应条件考察操作(以entry 17为例):向10mL Schlenk管中加入2-硝基苯并呋喃2a(32.6mg,0.2mmol)、配体L9(1.9mg,0.002mmol)、Cu(OAc)2(0.36mg,0.002mmol)和K2CO3(2.8mg,0.02mmol,10mol%)。将管用螺纹橡胶塞密封,氮气置换3次,然后通过注射器加入MTBE(1.0mL),混合物在25℃下搅拌40分钟。将亚胺叶立德1a(106.8mg,0.44mmol)溶于MTBE(1.0mL)中,混合物通过注射器加入反应液中,在0℃下搅拌10小时。用TLC跟踪反应,待反应完成后,使用乙酸乙酯/石油醚(体积比1/5)通过制备薄层色谱法纯化反应混合物,得到70.5mg橘黄色固体产物3aa,收率87%,dr值=14/1,97%ee。[ɑ]D 28=57.00(c=0.80,CH2Cl2).m.p.:115-116℃.HPLC CHIRALCEL ID,n-hexane/2-propanol=70/30,flow rate=0.8mL/min,temperature=25℃,λ=256nm,retention time:8.123min(major),9.938min(minor).TLC:Rf=0.24(petroleum ether:ethyl acetate=4:1).1H NMR(400MHz,CDCl3)δ7.93(s,1H),7.33–7.29(m,1H),7.27–7.23(m,1H),7.10–7.05(m,2H),6.92(d,J=7.2Hz,1H),6.89–6.85(m,2H),6.40–6.36(m,1H),6.85(s,1H),4.03(s,3H),3.77(s,1H),3.12(d,J=15.6Hz,1H),2.94(d,J=15.6Hz,1H),1.72(s,3H).13C NMR(150MHz,CDCl3)δ173.2,159.7,136.2,132.7,129.7,129.0,126.0,124.4,123.5,122.6,122.5,119.9,118.3,111.1,109.8,107.5,69.9,67.8,62.8,53.4,28.4,15.6.HRMS:exactmass calcd for C22H20N3O5(M+H)+requires m/z 406.1397,found m/z406.1388.

实施例2

Figure BDA0002310649070000061

向10mL Schlenk管中加入2-硝基苯并呋喃2a(32.6mg,0.2mmol),配体L9(1.9mg,0.002mmol)金属Cu(OAc)2(0.36mg,0.002mmol)和碱K2CO3(2.8mg,0.02mmol,10mol%)。将管用螺纹橡胶塞密封,氮气置换3次,然后通过注射器加入MTBE(1.0mL),混合物在25℃下搅拌40分钟。将亚胺叶立德1b(112.7mg,0.44mmol)溶于MTBE(1.0mL)中,混合物通过注射器加入反应液中,在0℃下搅拌10小时。用TLC跟踪反应,待反应完成后,使用乙酸乙酯/石油醚(体积比1/4)通过制备薄层色谱法纯化反应混合物,得到70.2mg橘黄色固体产物3ba,收率85%,dr值=16/1,95%ee。[ɑ]D 28=-8.33(c=0.72,CH2Cl2).m.p.:83-84℃.HPLCCHIRALCEL ID,n-hexane/2-propanol=70/30,flow rate=0.8mL/min,temperature=25℃,λ=256nm,retention time:7.963min(major),12.017min(minor).TLC:Rf=0.23(petroleum ether:ethyl acetate=4:1).1H NMR(400MHz,CDCl3)δ7.84(s,1H),7.34–7.29(m,1H),7.13(d,J=8.4Hz,1H),6.93–6.85(m,3H),6.84(s,1H),6.43–6.37(m,1H),4.85(s,1H),4.03(s,3H),3.74(s,1H),3.08(d,J=15.6Hz,1H),2.91(d,J=15.6Hz,1H),2.29(s,3H),1.70(s,3H).13C NMR(150MHz,CDCl3)δ173.3,159.8,134.6,132.7,129.7,129.0,129.0,126.3,124.4,124.2,123.5,122.5,118.1,110.7,109.8,107.0,69.9,67.7,62.8,53.4,28.4,21.5,15.7.HRMS:exact mass calcd for C23H22N3O5(M+H)+requires m/z420.1554,found m/z 420.1563.

实施例3

向10mL Schlenk管中加入2-硝基苯并呋喃2a(32.6mg,0.2mmol),配体L9(1.9mg,0.002mmol)金属Cu(OAc)2(0.36mg,0.002mmol)和碱K2CO3(2.8mg,0.02mmol,10mol%)。将管用螺纹橡胶塞密封,氮气置换3次,然后通过注射器加入MTBE(1.0mL),混合物在25℃下搅拌40分钟。将亚胺叶立德1c(119.7mg,0.44mmol)溶于MTBE(1.0mL)中,混合物通过注射器加入反应液中,在0℃下搅拌10小时。用TLC跟踪反应,待反应完成后,使用乙酸乙酯/石油醚(体积比1/4)通过制备薄层色谱法纯化反应混合物,得到77.4mg橘黄色固体产物3ca,收率89%,dr值=17/1,96%ee。[ɑ]D 28=-25.45(c=0.88,CH2Cl2).m.p.:94-96℃.HPLCCHIRALCEL ID,n-hexane/2-propanol=70/30,flow rate=0.8mL/min,temperature=25℃,λ=256nm,retention time:8.765min(major),13.665min(minor).TLC:Rf=0.23(petroleum ether:ethyl acetate=4:1).1H NMR(400MHz,CDCl3)δ7.89(s,1H),7.31(d,J=6.8Hz,1H),7.12(d,J=8.8Hz,1H),6.93–6.84(m,2H),6.72(dd,J=8.8,2.4Hz,1H),6.49(d,J=2.4Hz,1H),6.40–6.35(m,1H),4.84(s,1H),4.03(s,3H),3.78(br s,1H),3.71(s,3H),3.09(d,J=15.6Hz,1H),2.91(d,J=15.6Hz,1H),1.69(s,3H).13C NMR(150MHz,CDCl3)δ173.2,159.7,154.1,133.4,131.4,129.8,129.0,126.5,124.4,123.5,122.5,112.5,111.8,109.8,107.3,100.4,69.9,67.8,62.8,55.8,53.4,28.4,15.6.HRMS:exact masscalcd for C23H22N3O6(M+H)+requires m/z 436.1503,found m/z 436.1509.

实施例4

Figure BDA0002310649070000081

向10mL Schlenk管中加入2-硝基苯并呋喃2a(32.6mg,0.2mmol),配体L9(1.9mg,0.002mmol)金属Cu(OAc)2(0.36mg,0.002mmol)和碱K2CO3(2.8mg,0.02mmol,10mol%)。将管用螺纹橡胶塞密封,氮气置换3次,然后通过注射器加入MTBE(1.0mL),混合物在25℃下搅拌40分钟。将亚胺叶立德1d(140.8mg,0.44mmol)溶于MTBE(1.0mL)中,混合物通过注射器加入反应液中,在0℃下搅拌10小时。用TLC跟踪反应,待反应完成后,使用乙酸乙酯/石油醚(体积比1/4)通过制备薄层色谱法纯化反应混合物,得到81.2mg橘黄色固体产物3da,收率84%,dr值=17/1,98%ee。[ɑ]D 28=-43.67(c=0.60,CH2Cl2).m.p.:103-105℃.HPLCCHIRALCEL ID,n-hexane/2-propanol=70/30,flow rate=0.8mL/min,temperature=25℃,λ=254nm,retention time:6.293min(major),7.543min(minor).TLC:Rf=0.29(petroleum ether:ethyl acetate=4:1).1H NMR(400MHz,CDCl3)δ8.03(s,1H),7.30(d,J=6.4Hz,1H),7.19(s,1H),7.17–7.10(m,2H),6.96–6.87(m,2H),6.42–6.34(m,1H),4.84(s,1H),4.03(s,3H),3.80(s,1H),3.06(d,J=16.0Hz,1H),2.91(d,J=16.0Hz,1H),1.71(s,3H).13C NMR(150MHz,CDCl3)δ173.0,159.6,134.8,134.1,129.9,128.9,127.7,125.5,124.4,123.3,122.7,121.0,113.1,112.6,109.8,107.2,69.80,67.80,62.9,53.5,28.2,15.5.HRMS:exact mass calcd for C22H18BrN3NaO5(M+Na)+requires m/z 506.0322,foundm/z506.0318.

实施例5

Figure BDA0002310649070000091

向10mL Schlenk管中加入2-硝基苯并呋喃2a(32.6mg,0.2mmol),配体L9(1.9mg,0.002mmol)金属Cu(OAc)2(0.36mg,0.002mmol)和碱K2CO3(2.8mg,0.02mmol,10mol%)。将管用螺纹橡胶塞密封,氮气置换3次,然后通过注射器加入MTBE(1.0mL),混合物在25℃下搅拌40分钟。将亚胺叶立德1e(119.7mg,0.44mmol)溶于MTBE(1.0mL)中,混合物通过注射器加入反应液中,在0℃下搅拌10小时。用TLC跟踪反应,待反应完成后,使用乙酸乙酯/石油醚(体积比1/4)通过制备薄层色谱法纯化反应混合物,得到79.2mg橘黄色固体产物3ea,收率91%,dr值=17/1,96%ee。[ɑ]D 28=42.86(c=0.84,CH2Cl2).m.p.:89-91℃.HPLCCHIRALCEL IA,n-hexane/2-propanol=80/20,flow rate=0.6mL/min,temperature=25℃,λ=250nm,retention time:15.745min(minor),18.868min(major).TLC:Rf=0.24(petroleum ether:ethyl acetate=4:1).1H NMR(400MHz,CDCl3)δ7.90(s,1H),7.34(d,J=6.8Hz,1H),6.95(t,J=8.0Hz,1H),6.92–6.86(m,2H),6.84(d,J=8.4Hz,1H),6.44–6.38(m,1H),6.28(d,J=7.6Hz,1H),4.84(s,1H),4.02(s,3H),3.75–3.63(m,4H),3.26(d,J=16.4Hz,1H),3.17(d,J=16.4Hz,1H),1.68(s,3H).13C NMR(150MHz,CDCl3)δ173,4,159.7,154.5,137.6,130.9,129.6,129.0,124.6,123.7,123.3,122.4,116.6,109.7,107.5,104.4,100.2,70.0,67.6,62.5,55.4,53.3,30.2,15.7.HRMS:exact mass calcd forC23H22N3O6(M+H)+requires m/z 436.1503,found m/z 436.1505.

实施例6

Figure BDA0002310649070000101

向10mL Schlenk管中加入2-硝基苯并呋喃2a(32.6mg,0.2mmol),配体L9(1.9mg,0.002mmol)金属Cu(OAc)2(0.36mg,0.002mmol)和碱K2CO3(2.8mg,0.02mmol,10mol%)。将管用螺纹橡胶塞密封,氮气置换3次,然后通过注射器加入MTBE(1.0mL),混合物在25℃下搅拌40分钟。将亚胺叶立德1f(121.5mg,0.44mmol)溶于MTBE(1.0mL)中,混合物通过注射器加入反应液中,在0℃下搅拌10小时。用TLC跟踪反应,待反应完成后,使用乙酸乙酯/石油醚(体积比1/6)通过制备薄层色谱法纯化反应混合物,得到71.1mg橘黄色固体产物3fa,收率81%,dr值=15/1,92%ee。[ɑ]D 28=43.08(c=1.04,CH2Cl2).m.p.:91-93℃.HPLCCHIRALCEL OD-H,n-hexane/2-propanol=70/30,flow rate=0.8mL/min,temperature=25℃,λ=256nm,retention time:7.593min(major),11.335min(minor).TLC:Rf=0.22(petroleum ether:ethyl acetate=6:1).1H NMR(400MHz,CDCl3)δ8.00(s,1H),7.31–7.28(m,1H),7.25–7.23(m,1H),6.96(d,J=8.4Hz,1H),6.93–6.85(m,3H),6.41–6.37(m,1H),4.83(s,1H),4.03(s,3H),3.84(br s,1H),3.08(d,J=15.6Hz,1H),2.91(d,J=15.6Hz,1H),1.71(s,3H).13C NMR(150MHz,CDCl3)δ173.0,159.6,136.5,133.4,129.8,128.9,128.4,124.6,124.4,123.4,122.6,120.8,119.2,111.1,109.9,107.7,69.9,67.9,62.8,53.5,28.2,15.5.HRMS:exact mass calcd for C22H18ClN3NaO5(M+Na)+requires m/z462.0827,found m/z 462.0829.

实施例7

向10mL Schlenk管中加入2-硝基苯并呋喃2a(32.6mg,0.2mmol),配体L9(1.9mg,0.002mmol)金属Cu(OAc)2(0.36mg,0.002mmol)和碱K2CO3(2.8mg,0.02mmol,10mol%)。将管用螺纹橡胶塞密封,氮气置换3次,然后通过注射器加入MTBE(1.0mL),混合物在25℃下搅拌40分钟。将亚胺叶立德1g(112.7mg,0.44mmol)溶于MTBE(1.0mL)中,混合物通过注射器加入反应液中,在0℃下搅拌10小时。用TLC跟踪反应,待反应完成后,使用乙酸乙酯/石油醚(体积比1/4)通过制备薄层色谱法纯化反应混合物,得到72.9mg浅黄色固体产物3ga,收率87%,dr值=14/1,98%ee。[ɑ]D 28=13.2(c=1.00,CH2Cl2).m.p.:89-91℃.HPLC CHIRALCELID,n-hexane/2-propanol=70/30,flow rate=0.8mL/min,temperature=25℃,λ=250nm,retention time:7.065min(major),8.370min(minor).TLC:Rf=0.25(petroleumether:ethyl acetate=4:1).1H NMR(600MHz,CDCl3)δ8.05(s,1H),7.32–7.29(m,1H),7.23(d,J=8.4Hz,1H),7.09–7.05(m,2H),6.92–6.89(m,1H),6.88–6.85(m,2H),6.37–6.33(m,1H),4.84(s,1H),4.53–4.45(m,2H),3.82(br s,1H),3.12(d,J=15.6Hz,1H),2.95(d,J=15.6Hz,1H),1.71(s,3H),1.49(t,J=7.2Hz,3H).13C NMR(150MHz,CDCl3)δ172.7,159.7,136.2,132.7,129.6,129.1,126.0,124.3,123.6,122.5,122.5,119.8,118.3,111.1,109.8,107.6,69.9,67.9,62.9,62.4,28.3,15.6,14.4.HRMS:exact mass calcd forC23H22N3O5(M+H)+requires m/z 420.1554,found m/z 420.1556.

实施例8

向10mL Schlenk管中加入2-硝基苯并呋喃2a(32.6mg,0.2mmol),配体L9(1.9mg,0.002mmol)金属Cu(OAc)2(0.36mg,0.002mmol)和碱K2CO3(2.8mg,0.02mmol,10mol%)。将管用螺纹橡胶塞密封,氮气置换3次,然后通过注射器加入MTBE(1.0mL),混合物在25℃下搅拌40分钟。将亚胺叶立德1j(131.2mg,0.44mmol)溶于MTBE(1.0mL)中,混合物通过注射器加入反应液中,在0℃下搅拌10小时。用TLC跟踪反应,待反应完成后,使用乙酸乙酯/石油醚(体积比1/5)通过制备薄层色谱法纯化反应混合物,得到71.0mg浅黄色固体产物3ja,收率77%,dr值=11/1,90%ee。[ɑ]D 28=14.12(c=0.78,CH2Cl2).m.p.:96-97℃.HPLCCHIRALCEL IA,n-hexane/2-propanol=90/10,flow rate=0.6mL/min,temperature=25℃,λ=254nm,retention time:10.170min(minor),40.132min(major).TLC:Rf=0.21(petroleum ether:ethyl acetate=5:1).1H NMR(400MHz,CDCl3))δ7.97(s,1H),7.31–7.27(m,1H),7.24(d,J=8.0Hz,1H),7.11–7.01(m,2H),6.89(t,J=7.6Hz,1H),6.86–6.76(m,2H),6.37–6.21(m,1H),4.83(s,1H),4.03(s,3H),3.61(s,1H),3.13(d,J=15.6Hz,1H),2.93(d,J=15.6Hz,1H),2.28–2.14(m,1H),1.68–1.56(m,3H),1.38–1.25(m,4H),0.87(t,J=6.8Hz,3H).13C NMR(100MHz,CDCl3)δ173.3,159.6,136.4,131.4,129.5,129.3,126.0,124.2,123.6,122.6,122.4,119.7,118.2,111.0,109.5,109.1,71.9,69.8,62.4,53.4,32.4,29.6,28.3,25.3,22.6,14.1.HRMS:exact mass calcd for C26H28N3O5(M+H)+requires m/z 462.2023,found m/z 462.2021.

实施例9

Figure BDA0002310649070000131

向10mL Schlenk管中加入2-硝基苯并呋喃2b(35.4mg,0.2mmol),配体L9(1.9mg,0.002mmol)金属Cu(OAc)2(0.36mg,0.002mmol)和碱K2CO3(2.8mg,0.02mmol,10mol%)。将管用螺纹橡胶塞密封,氮气置换3次,然后通过注射器加入MTBE(1.0mL),混合物在25℃下搅拌40分钟。将亚胺叶立德1a(106.8mg,0.44mmol)溶于MTBE(1.0mL)中,混合物通过注射器加入反应液中,在0℃下搅拌10小时。用TLC跟踪反应,待反应完成后,使用乙酸乙酯/石油醚(体积比1/5)通过制备薄层色谱法纯化反应混合物,得到69.6mg橘黄色固体产物3ab,收率83%,dr值=14/1,94%ee。[ɑ]D 28=65.56(c=0.90,CH2Cl2).m.p.:113-115℃.HPLCCHIRALCEL ID,n-hexane/2-propanol=80/20,flow rate=0.6mL/min,temperature=25℃,λ=250nm,retention time:13.765min(major),20.677min(minor).TLC:Rf=0.28(petroleum ether:ethyl acetate=4:1).1H NMR(400MHz,CDCl3)δ7.94(s,1H),7.28–7.21(m,1H),7.12–7.06(m,3H),6.93(t,J=7.2Hz,1H),6.67(d,J=9.2Hz,1H),6.26(d,J=8.4Hz,1H),4.82(s,1H),4.03(s,3H),3.75(s,1H),3.11(d,J=15.6Hz,1H),2.95(d,J=16.0Hz,1H),2.21(s,3H),1.71(s,3H).13C NMR(150MHz,CDCl3)δ173.3,157.9,136.2,132.8,132.0,130.2,129.2,126.1,124.7,123.3,122.6,119.8,118.4,111.1,109.4,107.5,69.8,67.7,62.9,53.4,28.3,20.9,15.7.HRMS:exact mass calcd for C23H21N3NaO5(M+Na)+requires m/z442.1373,found m/z 442.1370.

实施例10

Figure BDA0002310649070000141

向10mL Schlenk管中加入2-硝基苯并呋喃2d(36.2mg,0.2mmol),配体L9(1.9mg,0.002mmol)金属Cu(OAc)2(0.36mg,0.002mmol)和碱K2CO3(2.8mg,0.02mmol,10mol%)。将管用螺纹橡胶塞密封,氮气置换3次,然后通过注射器加入MTBE(1.0mL),混合物在25℃下搅拌40分钟。将亚胺叶立德1a(106.8mg,0.44mmol)溶于MTBE(1.0mL)中,混合物通过注射器加入反应液中,在0℃下搅拌10小时。用TLC跟踪反应,待反应完成后,使用乙酸乙酯/石油醚(体积比1/4)通过制备薄层色谱法纯化反应混合物,得到73.6mg橘黄色固体产物3ad,收率87%,dr值=14/1,92%ee。[ɑ]D 28=22.50(c=1.30,CH2Cl2).m.p.:95-97℃.HPLCCHIRALCEL ID,n-hexane/2-propanol=80/20,flow rate=0.8mL/min,temperature=25℃,λ=250nm,retention time:9.445min(major),12.578min(minor).TLC:Rf=0.25(petroleum ether:ethyl acetate=4:1).1H NMR(400MHz,CDCl3)δ7.95(s,1H),7.28–7.24(m,1H),7.10(t,J=8.0Hz,2H),7.03(dd,J=7.6,2.4Hz,1H),6.95(t,J=7.2Hz,1H),6.58(td,J=8.8,2.8Hz,1H),6.31(dd,J=8.8,4.0Hz,1H),4.83(s,1H),4.03(s,3H),3.73(s,1H),3.14(d,J=15.6Hz,1H),2.95(d,J=15.6Hz,1H),1.71(s,3H).13C NMR(150MHz,CDCl3)δ173.0,160.2,136.2,132.5,129.2,125.9,125.8,125.3,123.0,122.8,122.7,120.2,118.4,113.5,111.2,107.4,69.7,67.7,62.2,53.5,28.4,15.7.HRMS:exact mass calcdfor C22H18FN3NaO5(M+Na)+requires m/z 446.1123,found m/z 446.1127.

实施例11

Figure BDA0002310649070000151

向10mL Schlenk管中加入2-硝基苯并呋喃2k(38.6mg,0.2mmol),配体L9(1.9mg,0.002mmol)金属Cu(OAc)2(0.36mg,0.002mmol)和碱K2CO3(2.8mg,0.02mmol,10mol%)。将管用螺纹橡胶塞密封,氮气置换3次,然后通过注射器加入MTBE(1.0mL),混合物在25℃下搅拌40分钟。将亚胺叶立德1a(106.8mg,0.44mmol)溶于MTBE(1.0mL)中,混合物通过注射器加入反应液中,在0℃下搅拌10小时。用TLC跟踪反应,待反应完成后,使用乙酸乙酯/石油醚(体积比1/4)通过制备薄层色谱法纯化反应混合物,得到72.2mg灰色固体产物3ak,收率83%,dr值=17/1,92%ee。[ɑ]D 28=-70.00(c=0.60,CH2Cl2).m.p.:130-132℃.HPLC CHIRALCELID,n-hexane/2-propanol=70/30,flow rate=0.8mL/min,temperature=25℃,λ=256nm,retention time:9.568min(major),13.188min(minor).TLC:Rf=0.23(petroleumether/ethyl acetate=4:1).1H NMR(400MHz,CDCl3)δ8.07(s,1H),7.17(d,J=8.0Hz,1H),7.10–7.02(m,2H),6.96–6.88(m,2H),6.80(t,J=7.6Hz,1H),6.47(d,J=8.4Hz,1H),4.85(s,1H),4.02(s,3H),3.83(s,1H),3.45(s,3H),3.12(d,J=15.6Hz,1H),2.98(d,J=15.6Hz,1H),1.74(s,3H).13C NMR(100MHz,CDCl3)δ173.2,148.5,143.9,136.3,132.6,129.1,126.1,124.9,123.1,122.5,119.8,118.3,116.5,113.2,111.3,107.7,70.0,68.0,63.4,56.2,53.4,28.4,15.6.HRMS:exact mass calcd for C23H22N3O6(M+H)+requires m/z436.1503,found m/z 436.1507.

实施例12

Figure BDA0002310649070000161

向10mL Schlenk管中依次加入3aa(40.5mg,0.1mmol),乙醇(1.5ml)和浓盐酸(0.08mL),在零度下缓慢加入锌粉(0.26g,4mmol)。将混合物在0℃下搅拌30min。待反应完成后,硅藻土过滤,用饱和NaHCO3溶液淬灭,二氯甲烷和水萃取,有机相用无水硫酸钠干燥,用甲醇/二氯甲烷(体积比1/20)通过制备薄层色谱法纯化反应混合物,得到28.9mg白色固体产物6,收率77%,97%ee。[ɑ]D 28=-53.24(c=1.00,CH2Cl2).m.p.:106-108℃.HPLCCHIRALCEL IE,n-hexane/2-propanol=70/30,flow rate=0.8mL/min,temperature=25℃,λ=256nm,retention time:9.575min(minor),17.278min(major).TLC:Rf=0.29(dichloromethane:methanol=20:1).1H NMR(400MHz,DMSO-d6)δ10.99(s,1H),10.04(s,1H),9.35(s,1H),7.33(d,J=8.0Hz,1H),7.07(d,J=7.6Hz,1H),7.02(t,J=8.0Hz,1H),6.87(t,J=7.2Hz,1H),6.83–6.76(m,1H),6.66(d,J=7.6Hz,1H),5.98(t,J=7.2Hz,1H),5.46(d,J=6.8Hz,1H),4.70(s,1H),3.73(s,3H),3.45(s,1H),2.87(d,J=15.6Hz,1H),2.10(d,J=15.6Hz,1H),1.74(s,3H).13C NMR(150MHz,DMSO-d6)δ174.4,162.4,154.6,137.2,136.0,128.3,127.0,126.7,123.2,120.7,118.6,117.5,113.9,111.3,105.9,66.6,61.0,52.1,49.3,48.6,26.6,17.4.HRMS:exact mass calcd for C22H22N3O3(M+H)+requires m/z 376.1656,found m/z 376.1654.

实施例13

Figure BDA0002310649070000162

向10mL Schlenk管中加入3aa(40.5mg,0.1mmol),将管用螺纹橡胶塞密封,氮气置换3次。用针头加入干燥的THF(1.0mL)溶液,反应液降温至-78℃,缓慢加入LiAlH4(0.2ml)。将混合物在-78℃下搅拌30min。待反应完成后,用15%氢氧化钠溶液(0.15ml)淬灭,乙酸乙酯和水萃取,有机相用无水硫酸钠干燥,用甲醇/二氯甲烷(体积比1/20)通过制备薄层色谱法纯化反应混合物,得到24.9mg灰色固体产物6,收率66%,94%ee。[ɑ]D 26=-40.00(c=0.90,CH2Cl2).m.p.:111-113℃ HPLC CHIRALCEL IA,n-hexane/2-propanol=70/30,flowrate=0.8mL/min,temperature=25℃,λ=256nm,retention time:6.442min(minor),15.342min(major).TLC:Rf=0.26(dichloromethane:methanol=20:1).1H NMR(400MHz,DMSO-d6)δ11.11(s,1H),7.34–7.31(m,1H),7.29(d,J=8.0Hz,1H),7.03(d,J=8.0Hz,1H),6.99(t,J=7.6Hz,1H),6.93–6.86(m,2H),6.81(t,J=7.2Hz,1H),6.45–6.41(m,1H),5.51(t,J=5.6Hz,1H),4.83(s,1H),3.92(dd,J=10.8,5.6Hz,1H),3.86(dd,J=11.2,5.6Hz,1H),3.66(s,1H),2.62(d,J=15.6Hz,1H),2.49(d,J=15.2Hz,1H),1.59(s,3H).13C NMR(150MHz,DMSO-d6)δ159.0,135.9,134.9,130.0,128.4,125.6,125.5,124.4,121.7,120.9,118.3,117.6,111.1,108.8,106.3,68.0,67.1,66.9,60.1,27.3,15.9.HRMS:exact masscalcd for C21H19N3NaO4(M+Na)+requires m/z 400.1268,found m/z 400.1265.

实施例14

Figure BDA0002310649070000171

向10mL Schlenk管中依次加入3aa(40.5mg,0.1mmol),三丁基氢化锡(135μL,0.5mmol)和AIBN(24.6mg,0.15mmol),甲苯(1mL),将混合物在80℃下搅拌1h。用TLC跟踪反应,待反应完成后,将混合物冷却至室温,用饱和KF溶液淬灭,乙酸乙酯和水萃取,有机相用无水硫酸钠干燥,用甲醇/二氯甲烷(体积比1/15)通过制备薄层色谱法纯化反应混合物,得到25.6mg米黄色固体产物6,收率71%,97%ee。[ɑ]D 26=-68.47(c=0.80,CH2Cl2).m.p.:191-192℃.HPLC CHIRALCEL IA,n-hexane/2-propanol=70/30,flow rate=0.8mL/min,temperature=25℃,λ=256nm,retention time:7.182min(minor),17.387min(major).TLC:Rf=0.28(dichloromethane:methanol=15:1).1H NMR(400MHz,CDCl3)δ7.93(s,1H),7.30(d,J=7.2Hz,1H),7.21(d,J=7.6Hz,1H),7.10–7.00(m,2H),6.90(t,J=7.2Hz,1H),6.75(t,J=7.2Hz,1H),6.68(t,J=7.2Hz,1H),6.19(d,J=8.0Hz,1H),5.09(d,J=10.4Hz,1H),4.41(d,J=10.4Hz,1H),3.95(s,3H),3.04(d,J=15.6Hz,1H),2.94(d,J=15.6Hz,1H),2.34(br s,1H),1.81(s,3H).13C NMR(150MHz,CDCl3)δ175.1,161.1,137.1,135.9,128.9,126.4,125.4,124.9,121.7,120.2,119.4,118.0,110.8,108.7,106.3,94.7,69.0,62.4,53.7,52.9,29.5,20.0.HRMS:exact mass calcd for C22H21N2O3(M+H)+requires m/z361.1547,found m/z 361.1544.

以上实施例描述了本发明的基本原理、主要特征及优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明原理的范围下,本发明还会有各种变化和改进,这些变化和改进均落入本发明保护的范围内。

15页详细技术资料下载
上一篇:一种医用注射器针头装配设备
下一篇:一种喹唑啉酮衍生物及其制备方法和应用

网友询问留言

已有0条留言

还没有人留言评论。精彩留言会获得点赞!

精彩留言,会给你点赞!